Menu
Search
|

Menu

Close
X

Auris Medical Holding AG EARS.OQ (NASDAQ Stock Exchange Capital Market)

0.29 USD
-0.00 (-1.31%)
As of Feb 16
chart
Previous Close 0.29
Open 0.30
Volume 113,533
3m Avg Volume 165,524
Today’s High 0.30
Today’s Low 0.28
52 Week High 1.05
52 Week Low 0.25
Shares Outstanding (mil) 34.33
Market Capitalization (mil) 32.28
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, CHF)
FY17
0
FY16
0
FY15
0
EPS (CHF)
FY17
-0.473
FY16
-0.893
FY15
-0.933
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
7.63
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
222.80
16.52
LT Debt to Equity (MRQ)
vs sector
142.77
12.22
Return on Investment (TTM)
vs sector
-112.79
14.43
Return on Equity (TTM)
vs sector
-167.38
16.13

EXECUTIVE LEADERSHIP

Thomas Meyer
Chairman of the Board, Chief Executive Officer, Since
Salary: --
Bonus: --
James Healy
Non-Executive Independent Vice Chairman of the Board, Since 2013
Salary: --
Bonus: --
Hernan Levett
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Anne Zoller
General Counsel, Since 2015
Salary: --
Bonus: --
Cindy McGee
Head of Investor Relations and Corporate Communications, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Bahnhofstrasse 21
ZUG   ZUG   6300

Phone: +4141.7297194

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

SPONSORED STORIES